In a preclinical model, an M-CSF blockade with the small inhibitor molecule BLZ945 decreased immunosuppressive macrophage (CD14/CD206) activation and increased inflammatory macrophage (HLA-DR/CD86) activation as well as DC and T cell infiltration, resulting in inhibition of tumor progression [35]. The gene discussed is CD86; the disease is neoplasm.